SPARC receives SEBI’s nod for Rs 250 crore rights issue

28 Jan 2016 Evaluate

Sun Pharma Advanced Research Company (SPARC) has received Securities and Exchange Board of India’s (Sebi’s) approval to raise up to Rs 250 crore through a rights issue. The company, which filed draft papers on September 18, 2015 seeking clearance from the markets regulator to raise funds through a rights issue, obtained the approval on January 22, 2016. The company will issue equity shares ‘aggregating up to Rs 25000 lakh to its existing equity shareholders on a rights basis. In a rights issue, shares are issued to existing investors as per their holding at a pre-determined price and ratio.

Sun Pharma Advanced Research Company is an international pharmaceutical company engaged in research and development of drugs and delivery systems.

Sun Pharma Adv. Res Share Price

133.25 -0.50 (-0.37%)
30-Dec-2025 09:58 View Price Chart
Peers
Company Name CMP
Syngene Internation. 649.35
Indegene 519.50
CMS Info Systems 340.25
Sagility 52.20
Smartworks Coworking 464.95
View more..
Register Now to get our Free Newsletter & much more!

© 2025 The Alchemists Ark Pvt. Ltd. All rights reserved. MoneyWorks4Me ® is a registered trademark of The Alchemists Ark Pvt. Ltd.

×